vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and IDEX Corporation (IEX). Click either name above to swap in a different company.
IDEX Corporation is the larger business by last-quarter revenue ($398.4M vs $247.1M, roughly 1.6× ANI PHARMACEUTICALS INC). IDEX Corporation runs the higher net margin — 30.1% vs 11.1%, a 19.0% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 16.7%). IDEX Corporation produced more free cash flow last quarter ($86.0M vs $29.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs -29.4%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
IDEX can refer to several things, including:International Defence Exhibition, a biennial arms and defense technology sales exhibition IDEX Corporation, a publicly listed company that makes fluidics systems and specialty engineered products Ideanomics, a publicly traded company that trades under the IDEX ticker symbol.
ANIP vs IEX — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $398.4M |
| Net Profit | $27.5M | $120.0M |
| Gross Margin | — | 99.9% |
| Operating Margin | 14.1% | 43.3% |
| Net Margin | 11.1% | 30.1% |
| Revenue YoY | 29.6% | 16.7% |
| Net Profit YoY | 367.5% | 25.7% |
| EPS (diluted) | $1.14 | $1.61 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 26 | — | $398.4M | ||
| Q1 26 | — | $407.7M | ||
| Q4 25 | $247.1M | $899.1M | ||
| Q3 25 | $227.8M | $878.7M | ||
| Q2 25 | $211.4M | $865.4M | ||
| Q1 25 | $197.1M | $814.3M | ||
| Q4 24 | $190.6M | $862.9M | ||
| Q3 24 | $148.3M | $798.2M |
| Q2 26 | — | $120.0M | ||
| Q1 26 | — | $128.3M | ||
| Q4 25 | $27.5M | $128.3M | ||
| Q3 25 | $26.6M | $127.8M | ||
| Q2 25 | $8.5M | $131.6M | ||
| Q1 25 | $15.7M | $95.5M | ||
| Q4 24 | $-10.3M | $123.2M | ||
| Q3 24 | $-24.2M | $119.1M |
| Q2 26 | — | 99.9% | ||
| Q1 26 | — | 94.9% | ||
| Q4 25 | — | 43.1% | ||
| Q3 25 | — | 44.5% | ||
| Q2 25 | — | 45.3% | ||
| Q1 25 | — | 45.3% | ||
| Q4 24 | — | 42.5% | ||
| Q3 24 | — | 44.3% |
| Q2 26 | — | 43.3% | ||
| Q1 26 | — | 45.0% | ||
| Q4 25 | 14.1% | 20.4% | ||
| Q3 25 | 15.9% | 21.1% | ||
| Q2 25 | 6.6% | 21.7% | ||
| Q1 25 | 13.3% | 17.4% | ||
| Q4 24 | -2.3% | 19.2% | ||
| Q3 24 | -13.8% | 21.0% |
| Q2 26 | — | 30.1% | ||
| Q1 26 | — | 31.5% | ||
| Q4 25 | 11.1% | 14.3% | ||
| Q3 25 | 11.7% | 14.5% | ||
| Q2 25 | 4.0% | 15.2% | ||
| Q1 25 | 8.0% | 11.7% | ||
| Q4 24 | -5.4% | 14.3% | ||
| Q3 24 | -16.3% | 14.9% |
| Q2 26 | — | $1.61 | ||
| Q1 26 | — | $1.71 | ||
| Q4 25 | $1.14 | $1.71 | ||
| Q3 25 | $1.13 | $1.70 | ||
| Q2 25 | $0.36 | $1.74 | ||
| Q1 25 | $0.69 | $1.26 | ||
| Q4 24 | $-0.45 | $1.61 | ||
| Q3 24 | $-1.27 | $1.57 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $586.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $4.0B |
| Total Assets | $1.4B | $6.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | — | $586.2M | ||
| Q1 26 | — | $580.0M | ||
| Q4 25 | $285.6M | $580.0M | ||
| Q3 25 | $262.6M | $593.8M | ||
| Q2 25 | $217.8M | $568.2M | ||
| Q1 25 | $149.8M | $594.1M | ||
| Q4 24 | $144.9M | $620.8M | ||
| Q3 24 | $145.0M | $633.2M |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | $1.8B | ||
| Q3 25 | — | $1.9B | ||
| Q2 25 | — | $1.9B | ||
| Q1 25 | — | $2.0B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $2.1B |
| Q2 26 | — | $4.0B | ||
| Q1 26 | — | $4.0B | ||
| Q4 25 | $540.7M | $4.0B | ||
| Q3 25 | $505.8M | $4.0B | ||
| Q2 25 | $436.8M | $4.0B | ||
| Q1 25 | $418.6M | $3.9B | ||
| Q4 24 | $403.7M | $3.8B | ||
| Q3 24 | $405.9M | $3.8B |
| Q2 26 | — | $6.9B | ||
| Q1 26 | — | $6.9B | ||
| Q4 25 | $1.4B | $6.9B | ||
| Q3 25 | $1.4B | $7.0B | ||
| Q2 25 | $1.3B | $6.9B | ||
| Q1 25 | $1.3B | $6.8B | ||
| Q4 24 | $1.3B | $6.7B | ||
| Q3 24 | $1.3B | $7.0B |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | 0.45× | ||
| Q3 25 | — | 0.48× | ||
| Q2 25 | — | 0.46× | ||
| Q1 25 | — | 0.50× | ||
| Q4 24 | — | 0.52× | ||
| Q3 24 | — | 0.55× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | — |
| Free Cash FlowOCF − Capex | $29.1M | $86.0M |
| FCF MarginFCF / Revenue | 11.8% | 21.6% |
| Capex IntensityCapex / Revenue | 0.5% | 4.4% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $654.3M |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $30.4M | $209.5M | ||
| Q3 25 | $44.1M | $203.5M | ||
| Q2 25 | $75.8M | $161.7M | ||
| Q1 25 | $35.0M | $105.7M | ||
| Q4 24 | $15.9M | $172.6M | ||
| Q3 24 | $12.5M | $205.3M |
| Q2 26 | — | $86.0M | ||
| Q1 26 | — | $189.8M | ||
| Q4 25 | $29.1M | $189.8M | ||
| Q3 25 | $38.0M | $188.7M | ||
| Q2 25 | $71.8M | $146.9M | ||
| Q1 25 | $32.5M | $91.4M | ||
| Q4 24 | $13.5M | $157.1M | ||
| Q3 24 | $7.7M | $191.6M |
| Q2 26 | — | 21.6% | ||
| Q1 26 | — | 46.6% | ||
| Q4 25 | 11.8% | 21.1% | ||
| Q3 25 | 16.7% | 21.5% | ||
| Q2 25 | 34.0% | 17.0% | ||
| Q1 25 | 16.5% | 11.2% | ||
| Q4 24 | 7.1% | 18.2% | ||
| Q3 24 | 5.2% | 24.0% |
| Q2 26 | — | 4.4% | ||
| Q1 26 | — | 15.6% | ||
| Q4 25 | 0.5% | 2.2% | ||
| Q3 25 | 2.7% | 1.7% | ||
| Q2 25 | 1.9% | 1.7% | ||
| Q1 25 | 1.3% | 1.8% | ||
| Q4 24 | 1.3% | 1.8% | ||
| Q3 24 | 3.2% | 1.7% |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | 1.63× | ||
| Q3 25 | 1.66× | 1.59× | ||
| Q2 25 | 8.87× | 1.23× | ||
| Q1 25 | 2.23× | 1.11× | ||
| Q4 24 | — | 1.40× | ||
| Q3 24 | — | 1.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
IEX
Segment breakdown not available.
